* Pre-clinical study shows safety and efficacy of device
* Co says no adverse events reported
July 12 (Reuters) - Canada’s Sernova Corp (SVA.V) said its experimental glucose-control device showed safety and efficacy in a pre-clinical study in pigs that were made diabetic.
The pigs treated with the company’s Cell Pouch System, which is implanted under the skin, achieved long-term glucose normalization throughout the course of the study, Sernova said in a statement.
The animal’s own islets, or insulin-producing tissues, were isolated from the pancreas and transplanted into the device that helps to provide a natural environment for the survival and function of therapeutic cells.
The study suggested the device could achieve glucose control with significantly fewer islets than normally required and reduce side-effects associated with the current standard-of-care where islets are directly injected into the portal vein of the liver, the company said.
Shares of the company closed at 11 Canadian cents Friday on the Toronto Venture Exchange. (Reporting by Krishnakali Sengupta in Bangalore; Editing by Gopakumar Warrier)